Overview

TPN-101 in Aicardi-Goutières Syndrome (AGS)

Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
A phase 2a multi-center, open-label single dose level study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
Phase:
Phase 2
Details
Lead Sponsor:
Transposon Therapeutics, Inc.